Table 3.

The recognition frequencies and antibody levels of circulating antibodies against microbial peptides in patients with anti-GBM disease, healthy controls, and patients with other diseases such as ANCA vasculitis and lupus nephritis

Peptide	Sequencea	Frequency in Anti-GBM Disease, n (%)	Antibody Level (OD Value)	Frequency in Healthy Controls, n (%)	Antibody Level (OD Value)	Frequency in Disease Controls, n (%)	Antibody Level (OD Value)	Cutoff Value (OD Value)
B7	GRWIVLWVEFQFKK	14 (30.4)	0.57 ± 0.26	0 (0)	−0.02 ± 0.13	0 (0)	0.04 ± 0.05	0.25
B10	WIVLSLWTGFTFKK	24 (52.2)	0.53 ± 0.29	0 (0)	−0.07 ± 0.11	1 (2.5)	0.02 ± 0.04	0.14
B11	WVLIALWTGFTFKK	29 (63.0)	0.56 ± 0.37	1 (4.5)	0.06 ± 0.11	0 (0)	0.02 ± 0.04	0.17
B12	WILIALWTGFTFKK	12 (26.1)	0.68 ± 0.33	1 (4.5)	0.06 ± 0.13	0 (0)	0.02 ± 0.02	0.31
B13	IWIALWAGFVSFKK	10 (21.7)	0.65 ± 0.34	2 (9.1)	0.01 ± 0.07	0 (0)	0.02 ± 0.04	0.15
B24	GQWISLWVYGFSKK	17 (37.0)	0.51 ± 0.35	0 (0)	−0.07 ± 0.09	1 (2.5)	0.01 ± 0.03	0.13
B25	KVVIWIALWTPLFAFL	10 (21.7)	0.60 ± 0.37	1 (4.5)	−0.01 ± 0.10	0 (0)	0.02 ± 0.03	0.19
B30	LWIALWAGVASFKK	15 (32.6)	0.51 ± 0.28	0 (0)	0.03 ± 0.09	0 (0)	0.02 ± 0.04	0.21
B35	GWIMLWGVGFFAKK	21 (45.7)	0.63 ± 0.46	0 (0)	−0.001 ± 0.08	3 (7.5)	0.04 ± 0.05	0.16

^aThe key amino acids are underlined.